Sulfonated chloroaluminum phthalocyanine (AlClPCS) has been considered in recent years as a new photosensitizer with promising use in photodynamic therapy (PDT) of cancer. In this work, its biological effects were studied in mice bearing S180 tumors. It was found in tissue distribution measurements that AlClPCS can be selectively accumulated in the tumor, the peak tumor concentration of AlClPCS occurs 36 h after administration, with a tumor:skin ratio of 3:1. The spectral transmittance measurement in the tumor, carried out in vivo at 48 h after administration of AlClPCS at 10 mg/kg, showed that AlClPCS accumulation in the tumor affects the light penetration to some extent at its 675 nm main absorption peak, but the transmittance at 675 nm is still comparable to that at 630 nm, the absorption peak of HPD. The temperature measurement in the tumor showed that the temperature increase is minimal under 100 mw/cm² irradiation. The tumor response to AlClPCS photodynamic therapy was encouraging. The cure rate of tumors (20 mice) reached 60% under conditions where the irradiation dose of red light was 180 J/cm² and the dose of AlClPCS administration was 10 mg/kg, showing AlClPCS has the potential to become a candidate for clinical photodynamic therapy.

Date Published: 5 March 1993
PDF: 7 pages
Proc. SPIE 1616, International Conference on Photodynamic Therapy and Laser Medicine, (5 March 1993);

Published in SPIE Proceedings Vol. 1616:
International Conference on Photodynamic Therapy and Laser Medicine
Junheng Li M.D., Editor(s)